Hims & Hers and Tempus AI are transforming digital health in distinct ways, but which platform looks more compelling right ...

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 2.2% in the morning session after Morgan ...

Hims & Hers Health, Inc. (HIMS) closed at $28.89 in the latest trading session, marking a -5.19% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 1.16% for the ...

Hims & Hers Health is significantly undervalued, with the market underestimating its growth potential and international expansion opportunities. Learn more about HIMS stock here.

Hims & Hers Health, Inc. faces short-term pressure after missing Novo’s partner list, but lab testing boosts long-term growth ...

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, built its growth strategy around a highly scalable, ...

The research, conducted by Talker Research on behalf of Hims, Inc., shows those expenses stretch across everyday life, from ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses lately. The San Francisco, CA-based ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

With plans starting at less than £1 a day or from £28 a month, Hims Hair is a hair loss treatment brand that uses ...

Hims & Hers posted record revenue this quarter. It is still selling patented weight loss drugs on its platform and is now getting sued by the pharmaceutical companies. Investors would do best to avoid ...

During 2025, Hims & Hers further deepened this foundation through targeted investments in data and AI. Leadership additions ...